USP <601>
USP <601> anchors performance testing for inhalation and nasal aerosols, sprays, and powders.
AccreditedStandards
Aerodynamic Particle Size TestingUSP <601>USP <1601>FDA MDI / DPI / nasal
Standards for NGI and Andersen cascade impactor APSD studies of inhalers, nebulizers, and nasal products.
Use this cluster when particle-size evidence must connect compendial method selection, FDA quality expectations, recovery controls, assay results, and reportable APSD metrics.
Standard roster
Individual standards in this cluster
USP <601>, USP <1601>, and FDA MDI / DPI guidance form the citation set; ARE Labs translates them into APSD setup, run controls, QA records, and report outputs.
USP <1601>
USP <1601> applies when nebulized products need characterization of delivery rate, total delivered drug, and aerodynamic aerosol assessment.
AlignedFDA MDI / DPI / nasal
FDA MDI / DPI quality guidance links APSD results to formulation controls, device performance, batch comparison, and CMC documentation.
AlignedPurpose & when to use
Aerodynamic Particle Size Distribution (APSD) testing uses cascade impactors to separate inhaled aerosol mass by aerodynamic cut point. This Standards cluster helps teams determine how USP <601>, USP <1601>, and FDA MDI / DPI quality guidance apply to NGI or Andersen impactor studies for inhalers, nebulizers, and related nasal products:
- MDI and DPI teams use USP <601> and FDA guidance when APSD, delivered dose, and fine-particle dose need one reviewable package.
- Nebulizer programs use USP <1601> when aerosol output, delivery rate, delivered drug, and aerodynamic assessment must share one method plan.
- Formulation or device changes use FDA quality expectations to compare APSD profiles, stage recovery, assay readiness, and batch-to-batch behavior.
- Investigations use USP <601> framing to separate device handling, flow control, stage recovery, extraction, and analytical contributors.
Use this cluster when the question extends beyond particle size to whether the APSD evidence remains traceable from device setup through recovery, assay, deviations, and final report interpretation.
Applicable to
Built around inhalation product decisions
The cluster applies when emitted aerosol performance depends on device handling, flow control, impactor recovery, and assay-ready collection across inhaled or nasal drug-delivery formats.
Standards in this group
What each citation controls
This page is a cluster, not three separate standard summaries. USP chapters define compendial performance or characterization frames, while FDA guidance sets quality expectations for development and manufacturing information. The summaries below stay at applicability level: what each citation controls, how it affects ARE Labs study design, and what source was verified.
USP
AccreditedUSP <601>
Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders - Performance Quality Tests
USP <601> anchors performance testing for inhalation and nasal aerosols, sprays, and powders. On APSD studies, it informs device setup, dose-delivery context, stage recovery, extraction readiness, and report language for MMAD, GSD, fine-particle dose, and related performance outputs.
USP official preview page verified from SG01 source notes on 2026-05-17.
USP
AlignedUSP <1601>
Products for Nebulization - Characterization Tests
USP <1601> applies when nebulized products need characterization of delivery rate, total delivered drug, and aerodynamic aerosol assessment. ARE Labs maps that frame to jet, mesh, ultrasonic, or investigational nebulizer setups with controlled operation, recovery timing, and assay-ready collection.
USP official preview page verified from SG01 source notes on 2026-05-17.
FDA
AlignedFDA MDI / DPI / nasal
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products - Quality Considerations
FDA MDI / DPI quality guidance links APSD results to formulation controls, device performance, batch comparison, and CMC documentation. ARE Labs uses it to connect impactor data with delivered dose, shot-weight checks, flow verification, assay readiness, and documented deviations.
FDA draft guidance page verified from SG01 source notes on 2026-05-17.
Accredited where held, aligned where followed
This page separates formal accreditation from standards alignment. ARE Labs can cite accredited USP <601> scope where applicable; USP <1601> and FDA MDI / DPI / nasal guidance are treated as aligned frameworks unless a separate scope is confirmed.
- USP <601>AccreditedAccredited APSD performance frame where scope applies.
- USP <1601>AlignedNebulizer characterization frame followed by protocol.
- FDA MDI / DPI / nasalAlignedQuality guidance translated into study and reporting controls.
Operational chain
How ARE Labs turns the standards into a study
The standards set the study frame, but the final APSD method still has to match the product, formulation, assay, and regulatory objective. ARE Labs translates USP and FDA expectations into setup, operation, recovery, adaptation, and reporting decisions.
01
Configuration
Select the impactor path
We map USP <601>, USP <1601>, or FDA MDI / DPI expectations to the NGI or ACI setup, flow condition, actuation approach, and collection strategy.
Protocol setup02
Operation
Control the aerosol run
Flow verification, leak checks, stage condition, device handling, and recovery timing are recorded so the USP or FDA frame is visible in the bench workflow.
Traceable run record03
Adaptation
Document fit-for-purpose choices
When no single standard governs the exact device or formulation, ARE Labs records the adaptation rationale while keeping USP <601>, USP <1601>, or FDA boundaries explicit.
Rationale log04
Reporting
Connect data to reviewable evidence
Reports connect APSD, MMAD, GSD, fine-particle metrics, recovery, deviations, limitations, and assay outputs back to USP and FDA expectations.
Review-ready reportData quality, QA/QC & documentation
APSD standards are useful only when the supporting records are clear. ARE Labs connects USP and FDA study requirements to traceable setup checks, run controls, recovery notes, assay readiness, raw data retention, and documented deviations. This allows reviewers to follow how each result was produced.
Connect setup to citation
USP <601> and USP <1601> runs link device setup, impactor configuration, flow checks, and collection timing to the selected study frame.
Preserve bench conditions
FDA MDI / DPI expectations make actuation handling, recovery timing, leak checks, and assay readiness part of the review trail.
Retain raw and reduced data
USP <601> APSD files retain stage mass, MMAD, GSD, fine-particle metrics, calculations, and calibration references for review.
Document method decisions
When a device does not map cleanly to USP or FDA language, ARE Labs records the rationale, limitation, and interpretation impact.
Separate scope from alignment
ISO 17025 review language distinguishes accredited USP <601> work from aligned USP <1601> or FDA guidance followed by protocol.
Why ARE Labs
ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.
Reviewed byJamie Balarashti - Weston Schaper
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported
Common questions
These questions explain how inhalation, formulation, and quality teams determine whether APSD work should follow USP <601>, USP <1601>, FDA MDI / DPI guidance, or a blended study plan. The answers outline the practical scoping decisions ARE Labs addresses before drafting the protocol, planning samples, and preparing the report.
Q. Which impactor path applies?
A. NGI is often the preferred impactor for modern inhalation characterization. ACI remains useful for legacy methods, comparability studies, and established submissions. ARE Labs selects the appropriate path based on product history, acceptance criteria, and review expectations.
Q. Does FDA guidance replace USP testing?
A. No. FDA guidance defines development and manufacturing quality expectations, while USP chapters often provide the compendial test structure. A study may cite both when the method design and reporting need to address both perspectives.
Q. What does aligned mean here?
A. Aligned means that ARE Labs follows the applicable standard or guidance through the study protocol. It does not imply formal accreditation unless the cited method is included in the accredited scope.
Q. How are paywalled standards handled?
A. ARE Labs links only to official publisher or regulator sources. If the full text is paywalled, the page explains the standard's applicability and laboratory implementation without reproducing protected method text.
Q. What is included in the report?
A. Depending on the protocol, reports may include setup records, stage mass, MMAD, GSD, fine-particle dose, recovery, assay outputs, raw data references, deviations, calibration records, and QA review.
Related services & devices
Related services & devices
Service
Particle Size Distribution (PSD) Testing
Primary service route for NGI, Andersen, real-time sizing, recovery, and cascade impactor reporting.Read more ->ServiceDose Uniformity & Emitted Dose
Pairs emitted-dose evidence with APSD for inhalation product performance packages.Read more ->ServiceSpray Pattern & Plume Geometry
Adds spray-shape and plume evidence for nasal products and actuation studies.Read more ->ServiceBreathing Simulation
Connects emitted aerosol performance to inhalation profiles and patient-use flow conditions.Read more ->DevicesMetered Dose Inhalers
Pressurized inhaler devices where APSD, delivered dose, and actuation handling often converge.Read more ->DevicesDry Powder Inhalers
Flow-dependent inhaler devices that use APSD to characterize powder emission behavior.Read more ->DevicesNebulizers
Jet, mesh, ultrasonic, and related nebulizer systems tied to USP <1601> characterization.Read more ->DevicesNasal Drug Spray Devices
Nasal formats where APSD may sit beside plume, spray pattern, and dose evidence.Read more ->Related clusters
Related standards clusters
APSD overlaps with neighboring inhalation clusters. These routes help teams move from cascade-impactor sizing into dose, nebulizer performance, spray imaging, or breathing-profile questions without losing the standards context.
Standards - Planned